IDEXX Q2 EPS $3.63 (+49% reported); raises FY2025 revenue and EPS guidance

IDEXX LABORATORIES INC /DE

2025-Q2 EPS reported $6.59 revenue$2,107,884,000

Q2 revenue $1,109M (+11% reported, +9% organic); CAG Diagnostics recurring revenue +9% reported, +7% organic.
Record quarterly instrument placements including nearly 2,400 IDEXX inVue Dx units.
FY2025 revenue guidance raised to $4,205M-$4,280M (prior $4,095M-$4,210M); organic growth outlook 7.0%-9.0%.
FY2025 EPS guidance raised to $12.40-$12.76 (prior $11.93-$12.43); reported growth 16%-20%.
Operating margin guidance improved to 31.3%-31.6%; comparable expansion 50-80 bps.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.